Literature DB >> 17510384

Extensive methylation is associated with beta-catenin mutations in hepatocellular carcinoma: evidence for two distinct pathways of human hepatocarcinogenesis.

Naoshi Nishida1, Takafumi Nishimura, Takeshi Nagasaka, Iwao Ikai, Ajay Goel, Goel Ajay, C Richard Boland.   

Abstract

Hepatocellular carcinoma (HCC) with p53 mutations is usually characterized by extensive chromosomal instability (CIN), whereas those with beta-catenin mutations have relatively less CIN and the molecular pathogenesis of these tumors is unknown. Methylation of CpG dinucleotides in the promoters of cancer-related genes is another characteristic feature of HCCs. The aim of this study was to determine the contribution of the methylator phenotype to HCC and its relationship to genomic instability. Fractional allelic loss (FAL) was determined using 400 microsatellite markers in 81 HCCs and 77 corresponding noncancerous livers as a measure of CIN. Methylation of 21 genetic loci was quantitated using combined bisulfite restriction analysis. Using hierarchical clustering analysis based upon the quantification of methylation levels, all HCCs were segregated into two groups characterized by either limited or extensive methylation. Mutations in the beta-catenin and p53 genes were determined by DNA sequencing. We found that the methylation levels were significantly higher in the HCCs than in noncancerous livers in 18 of the 21 loci (P values ranged from 0.035 to <0.0001). Among 18 loci, elevated levels of methylation at nine loci were significantly associated with beta-catenin mutations (P values ranged from 0.02 to <0.0001). In addition, the presence of beta-catenin mutations was associated with HCCs in the extensive methylation group (P < 0.0001), whereas p53 mutations correlated with high FAL scores (P = 0.0036). These data suggest that HCCs can be classified into two distinct categories based upon promoter methylation, CIN, and mutations of cancer-related genes. HCCs with extensive methylation harbor frequent beta-catenin mutations, whereas HCCs with high levels of CIN are associated with p53 mutations, suggesting the presence of two independent pathways for the pathogenesis of HCC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17510384     DOI: 10.1158/0008-5472.CAN-06-3464

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

2.  Hepatitis B virus-associated hepatocellular carcinoma from India: role of viral genotype and mutations in CTNNB1 (beta-catenin) and TP53 genes.

Authors:  Perumal Vivekanandan; Michael Torbenson; Banumathi Ramakrishna
Journal:  J Gastrointest Cancer       Date:  2011-03

Review 3.  Wnt signaling in liver cancer.

Authors:  Yutaka Takigawa; Anthony M C Brown
Journal:  Curr Drug Targets       Date:  2008-11       Impact factor: 3.465

Review 4.  DNA markers in molecular diagnostics for hepatocellular carcinoma.

Authors:  Ying-Hsiu Su; Selena Y Lin; Wei Song; Surbhi Jain
Journal:  Expert Rev Mol Diagn       Date:  2014-08-07       Impact factor: 5.225

Review 5.  Promoter methylation in the genesis of gastrointestinal cancer.

Authors:  Clement Richard Boland; Sung Kwan Shin; Ajay Goel
Journal:  Yonsei Med J       Date:  2009-06-23       Impact factor: 2.759

6.  Aberrant methylation of multiple tumor suppressor genes in aging liver, chronic hepatitis, and hepatocellular carcinoma.

Authors:  Naoshi Nishida; Takeshi Nagasaka; Takafumi Nishimura; Iwao Ikai; C Richard Boland; Ajay Goel
Journal:  Hepatology       Date:  2008-03       Impact factor: 17.425

7.  Genetic and epigenetic signatures in human hepatocellular carcinoma: a systematic review.

Authors:  Naoshi Nishida; Ajay Goel
Journal:  Curr Genomics       Date:  2011-04       Impact factor: 2.236

8.  Unique association between global DNA hypomethylation and chromosomal alterations in human hepatocellular carcinoma.

Authors:  Naoshi Nishida; Masatoshi Kudo; Takafumi Nishimura; Tadaaki Arizumi; Masahiro Takita; Satoshi Kitai; Norihisa Yada; Satoru Hagiwara; Tatsuo Inoue; Yasunori Minami; Kazuomi Ueshima; Toshiharu Sakurai; Naosuke Yokomichi; Takeshi Nagasaka; Ajay Goel
Journal:  PLoS One       Date:  2013-09-02       Impact factor: 3.240

9.  TP53 R72P polymorphism modulates DNA methylation in hepatocellular carcinoma.

Authors:  Khadija Rebbani; Agnès Marchio; Sayeh Ezzikouri; Rajaa Afifi; Mostafa Kandil; Olfa Bahri; Henda Triki; Abdellah Essaid El Feydi; Anne Dejean; Soumaya Benjelloun; Pascal Pineau
Journal:  Mol Cancer       Date:  2015-04-02       Impact factor: 27.401

10.  Demethylation of cancer/testis antigens and CpG ODN stimulation enhance dendritic cell and cytotoxic T lymphocyte function in a mouse mammary model.

Authors:  Jun-Zhong Sun; Lei Gao; Li Gao; Wei Wang; Nan Du; Juan Yang; Ling Wan; Fang Liu; Li-li Wang; Li Yu
Journal:  Biomed Res Int       Date:  2013-11-04       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.